Corrigendum to: Analysis of drug combinations: current methodological landscape (Pharmacology Research & Perspectives, (2015), 3, 3, (e00149), 10.1002/prp2.149);Analysis of drug combinations: current methodological landscape

Pharmacology Research and Perspectives

Volumn 3, Issue 3, 2015, Pages

  Foucquier, Julie ^a   Guedj, Mickael ^a  

^a PHARNEXT   (France)

Author keywords

Bliss; combination index; drug combination; loewe; synergy

Indexed keywords

ANATOMICAL CONCEPTS; CONCEPTUAL FRAMEWORK; DRUG INDUSTRY; KNOWLEDGE; MATHEMATICAL ANALYSIS; MEDICAL TECHNOLOGY; METHODOLOGY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RESEARCH; REVIEW; STATISTICAL MODEL; WORLD HEALTH ORGANIZATION;

EID: 84961741297     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.549     Document Type: Erratum

References (66)

1. Belen'kii MS, Schinazi RF (1994). Multiple drug effect analysis with confidence interval. Antiviral Res 25: 1–11.
2. Berenbaum M (1977) Synergy, additivism and antagonism in immunosuppression - critical review. Clin Exp Immunol 28: 1–18.
3. Berenbaum MC (1978). A method for testing for synergy with any number of agents. J Infect Dis 137: 122–130.
4. Berenbaum M (1989) What is synergy? Pharmacol Rev 41: 93–141.
5. Berthoud H-R (2013) Synergy: a concept in search of a definition. Endocrinology 154: 3974–3977.
6. Bliss CI (1939). The toxicity of poisons applied jointly. Ann Appl Biol 26: 585–615.
7. Boik JC, Narasimhan B (2010) An R package for assessing drug synergism/antagonism. J Stat Softw 34: 1–18.
8. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. (2003). Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100: 7977–7982.
9. Box GEP, Draper NR (1987) Empirical Model-Building and Response Surfaces. Wiley Series in Probability & Statistics, Oxford, England.
10. Breitinger H-G (2012) Drug synergy - mechanisms and methods of analysis. Pp. 143–166 in W. Acree, ed. Toxicity and Drug Testing, InTech, Rijeka, Croatia.
11. Carter W, Gennings C, Staniswalis J, Campbell E, White K (1988). A statistical approach to the construction and analysis of Isobolograms. Int J Toxicol 7: 963–973.
12. Caudle RM, Williams GM (1993). The misuse of analysis of variance to detect synergy in combination drug studies. Pain 55: 313–317.
13. Chou T-C (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621–681.
14. Chou T-C (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440–446.
15. Chou T-C, Talalay P (1983). Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450–454.
16. Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.
17. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. (2011). Systematic exploration of synergistic drug pairs. Mol Syst Biol 7: 544.
18. Frei W (1913) Versuche Uber Kombination Von Desinfektionsmitteln. Veit, Leipzig, Deutschland.
19. Geary N (2013). Understanding synergy. Am J Physiol Metab 304: E237–E253.
20. Gennings C, Carter WJ, Campbell E, Staniswalis J, Martin T, Martin B, et al. (1990). Isobolographic characterization of drug interactions incorporating biological variability. J Pharmacol Exp Ther 252: 208–217.
21. Glass G (2004). Cardiovascular combinations. Nat Rev Drug Discov 3: 731–732.
22. Goldoni M, Johansson C (2007) A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 21: 759–769.
23. Gordon Steel G, Peckham MJ (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol 5: 85–91.
24. Grabovsky Y, Tallarida RJ (2004). Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 310: 981–986.
25. Greco WR, Bravo G, Parsons JC (1995). The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331–385.
26. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32: 40–51.
27. Herrick TM, Million RP (2007) Tapping the potential of fixed-dose combinations. Nat Rev Drug Discov 6: 513–514.
28. Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. (2011). Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 103: 1222–1226.
29. Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. (2014). Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383: 166–175.
30. Jia J, Zhu F, Ma X, Cao Z, Cao ZW, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111–128.
31. Keith CT, Borisy AA, Stockwell BR (2005). Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71–78.
32. Kitano H (2007). A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202–210.
33. Larder BA, Kemp SD, Harrigan PR (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696–699.
34. Lee JJ, Kong M (2009). Confidence intervals of interaction index for assessing multiple drug interaction. Stat Biopharm Res 1: 4–17.
35. Lee JJ, Kong M (2011). Rebuttal to the response of Chou. Cancer Res 71: 2798–2800.
36. Lehár J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. (2007). Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 3: 80.
37. Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27: 659–666.
38. Loewe SMH (1926). über Kombination swirkungen. Arch für Exp Pathol 114: 313–326.
39. Loewe S (1927). Die Mischarznei. Versuch einer allgemeinen Pharmakologie der Arzneiombinationen. Klin Wochenshrift 6: 1077–1084.
40. Loewe S (1953). The problem of synergism and antagonisms of combined drugs. Arzneimittelforsch - Drug Res 3: 285–290.
41. Loewe S (1959). Randbemerkungen zur quantitativen Pharmakologie der Kombinationen. Arzneimittelforsch - Drug Res 9: 449–456.
42. Nelson HS (2001). Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 107: 398–416.
43. Nieuwenhuis S, Forstmann BU, Wagenmakers E-J (2011). Erroneous analyses of interactions in neuroscience: a problem of significance. Nat Neurosci 14: 1105–1107.
44. Ocana A, Amir E, Yeung C, Seruga B, Tannock IF (2012) How valid are claims for synergy in published clinical studies? Ann Oncol 23: 2161–2166.
45. Oversteegen L, Shah M, Rovini H (2007) HIV combination products. Nat Rev Drug Discov 6: 951–952.
46. Pangalos MN, Schechter LE, Hurko O (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6: 521–532.
47. Podolsky SH, Greene JA (2011). Combination drugs–hype, harm, and hope. N Engl J Med 365: 488–491.
48. Prichard MN, Shipman C (1990). A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14: 181–205.
49. Raffa RB, Stone DJJ, Tallarida RJ (2000). Discovery of “self-synergistic” spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J Pharmacol Exp Ther 295: 291–294.
50. Shafer SL (2012). All models are wrong. Anesthesiology 116: 240–241.
51. Shanks N, Greek R, Greek J (2009). Are animal models predictive for humans? Philos Ethics Humanit Med 4: 2.
52. Slinker BK (1998). The statistics of synergism. J Mol Cell Cardiol 30: 723–731.
53. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136–1144.
54. Straetemans R, O'Brien T, Wouters L, Van Dun J, Janicot M, Bijnens L, et al. (2005). Design and analysis of drug combination experiments. Biom J 47: 299–308.
55. Tallarida RJ (2001). Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865–872.
56. Tallarida RJ (2006). An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319: 1–7.
57. Tallarida RJ (2012). Revisiting the Isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther 342: 2–8.
58. Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, et al. (2013) Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 11:e1001609.
59. Wang Y, Zuo J, Wientjes MG (1997) Quantitation of interactive effects between anticancer agents using SAS Macros and SAS/GRAPH, in Annual international conference; 22nd, SAS USers Group.
60. Whitehead A, Su T-L, Thygesen H, Sperrin M, Harbron C (2013). Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies. Pharm Stat 12: 300–308.
61. Woodcock J, Griffin JP, Behrman RE (2011). Development of novel combination therapies. N Engl J Med 364: 985–987.
62. Yuan R (2000). Traditional Chinese medicine an approach to scientific proof and clinical validation. Pharmacol Ther 86: 191–198.
63. Zhao L, Wientjes MG, Au JL-S (2004). Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994–8004.
64. Zhao L, Au JL-S, Wientjes MG (2010). Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) 2: 241–249.
65. Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H (2014). A new bliss independence model to analyze drug combination data. J Biomol Screen 19: 817–821.
66. Zimmermann GR, Lehar J, Keith CT (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34–42.